ReviewFrontiers in immunology
Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm.
Review in Frontiers in immunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India.Complementary therapies in medicine · 2022Trial
- Prognostic model to identify and quantify risk factors for mortality among hospitalised patients with COVID-19 in the USA.BMJ open · 2021Trial
- Unbiased characterization of COVID-19 endotypes leads to prognostication of high-risk individuals using routine blood tests.Communications medicine · 2026Article
- The many faces of cytokine storm syndrome: immunopathogenic mechanisms and clinical implications for a better patient management.Clinical and experimental immunology · 2026Review
- Article
- The common genetic variant rs1278960 determining expression of Interferon-lambda predicts inflammatory response in critically ill COVID-19 patients.Scientific reports · 2025Article
- The Role of Vitamins, Magnesium, and Trace Elements in COVID-19 Treatment and Post-COVID-19 Rehabilitation: An Updated Overview.Current medicinal chemistry · 2025Review
- Development of a laboratory-based nomogram for predicting clinical outcomes in patients with severe COVID-19 undergoing glucocorticoid therapy.Frontiers in medicine · 2025Article
- Article
- Recent advances and evolving concepts in Still's disease.Nature reviews. Rheumatology · 2024Review
- Vitamin D Levels as a Marker of Severe SARS-CoV-2 Infection.Life (Basel, Switzerland) · 2024Article
- Observational
- Ferritin and myalgic encephalomyelitis/chronic fatigue syndrome in post COVID-19, an unexpected facet of the hyperferritinemic syndrome?Journal of psychosomatic research · 2023Article
- Article
- The specialized pro-resolving lipid mediator Protectin D1 affects macrophages differentiation and activity in Adult-onset Still's disease and COVID-19, two hyperinflammatory diseases sharing similar transcriptomic profiles.Frontiers in immunology · 2023Article
- Development and validation of prognostic scoring system for COVID-19 severity in South India.Irish journal of medical science · 2022Article
- Two flares of Still's disease after two doses of the ChAdOx1 vaccine.Clinical rheumatology · 2022Review
- Clinical Predictors of Response to Tocilizumab: A Retrospective Multicenter Study.Turkish thoracic journal · 2022Article
- New-onset Adult-onset Still's disease-like syndrome after ChAdOx1 nCoV-19 vaccination-a case series with review of literature.Clinical rheumatology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19), an acute respiratory disease caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has been declared as a worldwide public health emergency. Interestingly, severe COVID-19 is characterized by fever, hyperferritinemia, and a hyper-inflammatory process with a massive release of pro-inflammatory cytokines, which may be responsible for the high rate of mortality. These findings may advocate for a similarity between severe COVID-19 and some challenging rheumatic diseases, such as adult onset Still's disease, secondary hemophagocytic lymphohistiocytosis, and catastrophic anti-phospholipid syndrome, which have been included in the "hyperferritinemic syndrome" category. Furthermore, as performed in these hyper-inflammatory states, severe COVID-19 may benefit from immunomodulatory therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.